Abramson Cancer Center at Penn Medicine
Quick facts
Marketed products
- Prevnar · Other
- Vemurafenib (VEM) · Oncology
Vemurafenib is a small-molecule inhibitor that selectively blocks the BRAF V600E kinase mutation found in melanoma and other cancers. - Vitamin D3 cholecalciferol)
Phase 3 pipeline
- Capecitabine Oral Product · Oncology
Capecitabine is a prodrug that is converted to fluorouracil in the body, which inhibits thymidylate synthase and disrupts DNA synthesis to kill rapidly dividing cancer cells.
Phase 2 pipeline
- Gliolan · Other
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Abramson Cancer Center at Penn Medicine portfolio CI brief
- Abramson Cancer Center at Penn Medicine pipeline updates RSS
Frequently asked questions about Abramson Cancer Center at Penn Medicine
What are Abramson Cancer Center at Penn Medicine's marketed drugs?
Top marketed products include Prevnar, Vemurafenib (VEM), Vitamin D3 cholecalciferol).
What is Abramson Cancer Center at Penn Medicine's pipeline?
Abramson Cancer Center at Penn Medicine has 1 drugs in Phase 3, 1 in Phase 2, 3 in Phase 1. Late-stage candidates include Capecitabine Oral Product.
Related
- Prevnar · Other
- Vemurafenib (VEM) · Oncology
- Vitamin D3 cholecalciferol)
- Sector hub: All tracked pharma companies